{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T17:44:09Z","timestamp":1792863849048,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Altern Med"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12906-015-0955-2","type":"journal-article","created":{"date-parts":[[2015,12,4]],"date-time":"2015-12-04T14:04:41Z","timestamp":1449237881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Study on health hazards through medicines purchased on the Internet: a cross-sectional investigation of the quality of anti-obesity medicines containing crude drugs as active ingredients"],"prefix":"10.1186","volume":"15","author":[{"given":"Naoko","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Numano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,4]]},"reference":[{"key":"955_CR1","unstructured":"World Health Organization: Medicines: spurious\/falsely-labelled\/ falsified\/counterfeit (SFFC) medicines. Fact sheet N\u00b0275, May 2012 [ http:\/\/www.who.int\/mediacentre\/factsheets\/fs275\/en\/ ] Accessed on June 18, 2013."},{"key":"955_CR2","unstructured":"WHO: WHO\u2019s role in the prevention and control of medical products of compromised quality, safety and efficacy such as substandard\/spurious\/falselylabelled\/falsified\/counterfeit medical products. February 2011. [ http:\/\/apps.who.int\/gb\/ssffc\/pdf_files\/A_SSFFC_WG3Rev1-en.pdf ]."},{"key":"955_CR3","doi-asserted-by":"publisher","first-page":"e7381","DOI":"10.1136\/bmj.e7381","volume":"345","author":"A Attaran","year":"2012","unstructured":"Attaran A, Barry D, Basheer S, Bate R, Benton D, Chauvin J, et al. How to achieve international action on falsified and substandard medicines. BMJ. 2012;345:e7381. [ http:\/\/www.bmj.com\/content\/345\/bmj.e7381.full.pdf+html ].","journal-title":"BMJ"},{"key":"955_CR4","unstructured":"Ministry of Health, Labour and Welfare: Information for those who are bringing medicines for personal use into Japan. [ http:\/\/www.mhlw.go.jp\/english\/policy\/health-medical\/pharmaceuticals\/01.html ]."},{"key":"955_CR5","unstructured":"The Ministry of Health, Labour and Welfare in Japan: in Japanese. [ http:\/\/www.mhlw.go.jp\/topics\/bukyoku\/iyaku\/kojinyunyu\/050609-1.html ] Accessed on September 10, 2015."},{"key":"955_CR6","unstructured":"The U.S. Food and Drug Administration: What can I do to help ensure I do not receive or take counterfeit medicine? September 19, 2013. [ http:\/\/www.fda.gov\/drugs\/resourcesforyou\/consumers\/buyingusingmedicinesafely\/counterfeitmedicine\/ucm235434.htm ] Accessed on September 10, 2015."},{"key":"955_CR7","unstructured":"The U.S. Food and Drug Administration: Helping Patients Avoid Counterfeit Drugs over the Internet. FDA Patient Safety News. Show #67, September 2007. [ http:\/\/www.fda.gov\/downloads\/Safety\/FDAPatientSafetyNews\/UCM417854.pdf ] Accessed on September 10, 2015."},{"key":"955_CR8","unstructured":"European Medicines Agency: Falsified medicines. [ http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/special_topics\/general\/general_content_000186.jsp&mid=WC0b01ac058002d4e8 ] Accessed on September 10, 2015."},{"key":"955_CR9","unstructured":"Medicines and Healthcare Products Regulatory Agency in the United Kingdom. Counterfeit medicines: what pharmacists should know. December 11, 2014. [ https:\/\/www.gov.uk\/drug-safety-update\/counterfeit-medicines-what-pharmacists-should-know ] Accessed on September 10, 2015."},{"key":"955_CR10","unstructured":"Medicines and Healthcare Products Regulatory Agency in the United Kingdom. Yellow Card extended to include devices, counterfeits and defective medicines. January 22, 2015. [ https:\/\/www.gov.uk\/drug-safety-update\/yellow-card-extended-to-include-devices-counterfeits-and-defective-medicines ] Accessed on September 10, 2015."},{"key":"955_CR11","unstructured":"Health Canada: Policy on Counterfeit Health Products (POL-0048). [ http:\/\/www.hc-sc.gc.ca\/dhp-mps\/compli-conform\/activit\/pol_0048_counterfeit-contrefacon-eng.php ] Accessed on September 10, 2015."},{"key":"955_CR12","unstructured":"Therapeutic Goods Administration in Australia: Counterfeit medicines and medical devices. November 6, 2015. [ http:\/\/www.tga.gov.au\/counterfeit-medicines-and-medical-devices ] Accessed on December 4, 2015."},{"key":"955_CR13","doi-asserted-by":"crossref","unstructured":"Kimura K, Okumura J, Honma T, Osawa T, Araki R, Tanimoto T: Public health implication of personal import of medicines through internet brokers. Iryo To Shakai 18, 459-472, 2008. In Japanese. [ https:\/\/www.jstage.jst.go.jp\/article\/iken\/18\/4\/18_4_459\/_pdf]","DOI":"10.4091\/iken.18.459"},{"key":"955_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4091\/iken.21.55","volume":"21","author":"K Kimura","year":"2011","unstructured":"Kimura K, Honma T, Tanimoto T, Takao C, Okumura J, Yoshida N, et al. Public health implication of personal import of medicines through internet brokers (2): buying Anti-obesity Agents on-line. Iryo To Shakai. 2011;21:55\u201366. In Japanese. [ https:\/\/www.jstage.jst.go.jp\/article\/iken\/21\/1\/21_1_55\/_article\/-char\/ja\/ ].","journal-title":"Iryo To Shakai"},{"key":"955_CR15","first-page":"134","volume":"28","author":"R Araki","year":"2010","unstructured":"Araki R, Okumura J, Akazawa M, Kimura K. Survey of consumers\u2019 attitude toward personal import of medicines. Japanese J Soc Pharm. 2010;28:134\u20135 (in Japanese).","journal-title":"Japanese J Soc Pharm"},{"key":"955_CR16","doi-asserted-by":"crossref","unstructured":"Khan MH, Tanimoto T, Nakanishi Y, Yoshida N, Tsuboi H, Kimura K: Public health concerns for anti-obesity medicines imported for personal use through the internet: a cross-sectional study. BMJ Open 2, 2012. [ http:\/\/bmjopen.bmj.com\/content\/2\/3\/e000854.full.pdf+html ]","DOI":"10.1136\/bmjopen-2012-000854"},{"key":"955_CR17","unstructured":"Ministry of Health, Labour and Welfare: the list of plant-origin materials used mainly as pharmaceutical medicine. In Japanese. [ http:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-11130500-Shokuhinanzenbu\/0000086062.pdf ]"},{"key":"955_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2471\/BLT.10.020410","volume":"88","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. Growing threat from counterfeit medicines. Bull World Health Organ. 2010;88:247\u20138.","journal-title":"Bull World Health Organ"},{"key":"955_CR19","unstructured":"Ministry of Health, Labour and Welfare: The Japanese Pharmacopoeia 16th edition. 2011. [ http:\/\/jpdb.nihs.go.jp\/jp16e\/ ]."},{"issue":"4","key":"955_CR20","first-page":"301","volume":"53","author":"A Tanaka","year":"2000","unstructured":"Tanaka A, Nishida R, Maeda K, Sugawara A, Kuwahara T. Chinese herb nephropathy in Japan presents adult-onset Fanconi syndrome: could different components of aristolochic acids cause a different type of Chinese herb nephropathy? Clin Nephrol. 2000;53(4):301\u20136.","journal-title":"Clin Nephrol"},{"key":"955_CR21","doi-asserted-by":"crossref","unstructured":"Tanaka A, Nishida R, Yoshida T, Koshikawa M, Goto M, Kuwahara T: Outbreak of Chinese herb nephropathy in Japan: are there any differences from Belgium? Intern Med. 40: 296-300, 2001. [ https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine1992\/40\/4\/40_4_296\/_article ].","DOI":"10.2169\/internalmedicine.40.296"},{"key":"955_CR22","unstructured":"Ministry of Health, Labour and Welfare: Health hazards by Chinese Weight-loss Dietary Supplement (unapproved medicines). July 12, 2006. In Japanese. [ http:\/\/www.mhlw.go.jp\/houdou\/2002\/07\/h0719-3.html ] Accessed on June 20, 2013."},{"issue":"2","key":"955_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0028-3908(89)90048-8","volume":"28","author":"GP Luscombe","year":"1989","unstructured":"Luscombe GP, Hopcroft RH, Thomas PC, Buckett WR. The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology. 1989;28(2):129\u201334. [ http:\/\/ac.els-cdn.com\/0028390889900488\/1-s2.0-0028390889900488-main.pdf?_tid=64303698-065b-11e4-a0fe-00000aab0f6b&acdnat=1404795212_2d759e9f17251c553134acb7f746a0a1 ].","journal-title":"Neuropharmacology"},{"issue":"2-3","key":"955_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0014-2999(02)01423-1","volume":"440","author":"CA Luque","year":"2002","unstructured":"Luque CA, Rey JA. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol. 2002;440(2-3):119\u201328. [ http:\/\/ac.els-cdn.com\/S0014299902014231\/1-s2.0-S0014299902014231-main.pdf?_tid=4b45166c-065b-11e4-a752-00000aacb362&acdnat=1404795170_a6f3b37b1fc70bd5b0db00408daf1153 ].","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 2","key":"955_CR25","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.2337\/dc11-s205","volume":"34","author":"AJ Scheen","year":"2011","unstructured":"Scheen AJ. Sibutramine on cardiovascular outcome. Diabetes Care. 2011;34 Suppl 2:S114\u20139. [ http:\/\/care.diabetesjournals.org\/content\/34\/Supplement_2\/S114.long ].","journal-title":"Diabetes Care"},{"issue":"Suppl. L","key":"955_CR26","doi-asserted-by":"publisher","first-page":"L44","DOI":"10.1093\/eurheartj\/sui086","volume":"7","author":"WPT James","year":"2005","unstructured":"James WPT. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J. 2005;7(Suppl L):L44\u20138. [ http:\/\/eurheartjsupp.oxfordjournals.org\/content\/7\/suppl_L\/L44.full.pdf+html ].","journal-title":"Eur Heart J"},{"issue":"10","key":"955_CR27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa1003114","volume":"363","author":"WP James","year":"2010","unstructured":"James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905\u201317. [http:\/\/www.nejm.org\/doi\/pdf\/ 10.1056\/NEJMoa1003114 ].","journal-title":"N Engl J Med"},{"key":"955_CR28","unstructured":"U.S. Food and Drug Administration: Meridia (sibutramine): Market Withdrawal Due to Risk of Serious Cardiovascular Events. August 2010. [ http:\/\/www.fda.gov\/safety\/medwatch\/safetyinformation\/safetyalertsforhumanmedicalproducts\/ucm228830.htm ] Accessed on May 21, 2014."},{"key":"955_CR29","doi-asserted-by":"crossref","unstructured":"Mackey TK, Aung P, Liang BA: Illicit Internet availability of drugs subject to recall and patient safety consequences. Int J Clin Pharm. 2015 Jul 7. In press. [ http:\/\/link.springer.com\/article\/10.1007%2Fs11096-015-0154-8 ].","DOI":"10.1007\/s11096-015-0154-8"},{"key":"955_CR30","unstructured":"European Medicines Agency: Sibutramine. August 2010. [ http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Sibutramine\/human_referral_000219.jsp ]."},{"key":"955_CR31","doi-asserted-by":"crossref","unstructured":"Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, Vanhaelen M, Dratwa M, Richard C, Vandervelde D, Verbeelen D, Jadoul M: Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 13; 341 (8842): 387-91, 1993. [ http:\/\/www.sciencedirect.com\/science\/article\/pii\/0140673693929842 ].","DOI":"10.1016\/0140-6736(93)92984-2"},{"issue":"23","key":"955_CR32","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1056\/NEJM200006083422301","volume":"342","author":"JL Nortier","year":"2000","unstructured":"Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342(23):1686\u201392. [http:\/\/www.nejm.org\/doi\/pdf\/ 10.1056\/NEJM200006083422301 ].","journal-title":"N Engl J Med"},{"issue":"3","key":"955_CR33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1742-1241.2011.02826.x","volume":"66","author":"G Jackson","year":"2012","unstructured":"Jackson G, Patel S, Khan S. Assessing the problem of counterfeit medications in the United Kingdom. Int J Clin Pract. 2012;66(3):241\u201350.","journal-title":"Int J Clin Pract"},{"issue":"4","key":"955_CR34","first-page":"216","volume":"7","author":"EA Blackstone","year":"2014","unstructured":"Blackstone EA, Fuhr Jr JP, Pociask S. The health and economic effects of counterfeit drugs. Am Health Drug Benefits. 2014;7(4):216\u201324.","journal-title":"Am Health Drug Benefits"},{"issue":"2","key":"955_CR35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ki.2008.129","volume":"74","author":"FD Debelle","year":"2008","unstructured":"Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008;74(2):158\u201369.","journal-title":"Kidney Int"}],"container-title":["BMC Complementary and Alternative Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-015-0955-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12906-015-0955-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-015-0955-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T05:51:48Z","timestamp":1567403508000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-015-0955-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["955"],"URL":"https:\/\/doi.org\/10.1186\/s12906-015-0955-2","relation":{},"ISSN":["1472-6882"],"issn-type":[{"value":"1472-6882","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"article-number":"430"}}